In a report released on Friday October 07, 2016 Panmure Gordon hold steady the stock price target of EKF Diagnostics Holdings PLC (LON:EKF) from 17.50GBX to 17.50GBX reporting a possible upside of 0.02%.

Previously on 09/12/2016, N+1 Singer reported on EKF Diagnostics Holdings PLC (LON:EKF) increased the target price from 18.00GBX to 19.00GBX. At the time, this indicated a possible upside of 0.20%.

Just yesterday EKF Diagnostics Holdings PLC (LON:EKF) traded 15.15% higher at 17.13GBX. EKF Diagnostics Holdings PLC’s 50-day moving average is 14.89GBX and its 200-day moving average is 13.22GBX. The last closing price is up 27.39% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 1,267,757 shares of EKF traded hands, up from an average trading volume of 717,786

Recent Performance Chart

EKF Diagnostics Holdings PLC has 52 week low of 7.00GBX and a 52 week high of 23.45GBX and has a market capitalization of 0 GBX.

In addition to Panmure Gordon reporting its stock price target, a total of 2 brokers have issued a research note on the company. The average stock price target is 18.50GBX with 0 brokers rating the stock a strong buy, 1 broker rating the stock a buy, 1 broker rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On EKF Diagnostics Holdings PLC (LON:EKF)

EKF Diagnostics Holdings plc is engaged in developing, manufacturing and supplying of products and services into the in-vitro diagnostic (IVD) market place. The Company manufactures and sells diagnostic instruments, reagents and certain ancillary products. The Company's point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases. The Company's Central Laboratory division includes a range of products for use in both large and small laboratory facilities. Its subsidiary, EKF Life Sciences, provides bulk diagnostic enzyme manufacturing and fermentation services. EKF Life Sciences specializes in producing enzymes, including Salicylate Hydroxylase and Beta-Hydroxybutyrate Dehydrogenase. Its products include Quo-Test A1c, Biosen C-Line and Biosen S-Line, STAT-Site M B-HB analyzer, sTNFR1 biomarker test kits and Altair 240.